Recent advances in epigenetics indicate the involvement of several epigenetic modifications in the pathogenesis of acute kidney injury (AKI). The purpose of this review is to summarize our understanding of recent advances in the epigenetic regulation of AKI and provide mechanistic insight into the role of acetylation, methylation, and microRNA expression in the pathological processes of AKI.
INTRODUCTION
Acute kidney injury (AKI), characterized by a rapid decline in renal function, is a serious disease with an unacceptably high mortality rate and no effective treatment beyond supportive care. The mortality of AKI has been estimated to be about 30-70%, depending on the severity of injury [1] . The sequelae of AKI are severe and manifested by an increased risk of short-term and long-term mortality, persistent chronic kidney disease and accelerated likelihood of end-stage renal disease [2] . Although much progress has been made in understanding the cellular and molecular basis of AKI, there has been little improvement in its high mortality rate in the past several decades [2] [3] [4] . Therefore, exploring its pathogenesis, in order to be able to develop an effective treatment for AKI, is urgently needed. AKI can be induced by numerous insults, such as sepsis, ischemia/reperfusion (I/R), rhabdomyolysis, contrast media, or other nephrotoxins [5, 6] . Studies have demonstrated that renal tubular cell death and tubulointerstitial inflammation are two important determinants of tissue damage and renal failure. The proximal straight tubule in the outer medulla of the kidney is particularly susceptible to I/R injury. After severe injury, some renal tubular cells die by apoptosis and necrosis and the remaining surviving tubular cells undergo regeneration. During the regenerative process, renal epithelial cells dedifferentiate and then migrate and proliferate to replace lost cells, finally resulting in morphological and functional recovery of the renal epithelium [7] . Animal studies have indicated that the kidney possesses a remarkable regenerative capacity after injury, its function can be completely resumed if the injury is mild [3] . Although the specific mechanism responsible for renal regeneration after AKI is incompletely understood, it has been recognized that some molecules such as vimentin, Pax-2, and neural cell adhesion molecule, which are expressed in metanephric mesenchyme but not in mature kidneys, are re-expressed in renal epithelial cells during recovery from acute injury [7, 8] . This suggests that the process of renal restoration after AKI may reflect that of early kidney development.
Kidney development can be regulated by epigenetic modifications. Epigenetics refers to the modulation of gene expression via posttranslational modification of protein complexes associated with DNA without changing DNA sequence, including acetylation, methylation, phosphorylation, ubiquitinylation, sumoylation, carbonylation, and glycosylation, as well as expression of microRNA (miRNA). Epigenetic information is encoded through covalent modification of histones and DNA. Chromatin, a complex of DNA and proteins inside the nuclei of eukaryotic cells, plays an important role in transcription, DNA replication, and repair. The fundamental repeating units of chromatin are composed of the nucleosome, which is formed by a 146 base pairs of DNA wrapped around histone protein cores (two H2A/H2B dimers and a H3/H4 tetramer) [9] . Remodeling of chromatin between relatively 'open' and 'closed' forms has a crucial role in epigenetic modulation of gene expression [10] . Chromatin modifying enzymes can catalyze addition or removal of posttranslational modifications. For example, histone deacetylases (HDACs) can remove acetyl groups from histone proteins and are required for growth and differentiation of the embryonic kidney and regulation of essential genes involved in these processes, including Osr1, Eya1, Pax2/8, WT1, Gdnf, Wnt9b, Sfrp1/2, and Emx2 [11, 12] . Pax2 can provide the DNA binding specificity for an MLL3/4 Trithorax-like protein complex that promotes histone H3, lysine 4 methylation (H3K4me). Studies in mice indicated that reducing histone H3K4 methyltransferase activity could alter cellular phenotypes, leading to changes in gene expression patterns in podocytes [13] .
Numerous studies have shown that epigenetic processes are involved in the pathogenesis of AKI. In this article, we discuss recent advances in the epigenetics of AKI, with the focus on acetylation, methylation, and change of miRNA expression.
ACETYLATION AND ACUTE KIDNEY INJURY
The condensed repressive chromatin structure is partially dependent on the electrostatic interaction of the positive charge on histones and the negative charge on DNA [1] . Acetylation of the lysine residues at the N termini of histones removes the positive charges, thereby reducing the affinity of histones for the negatively charged DNA, subsequently altering the compact chromatin to a more relaxed structure for the recruitment of activators or inhibitors of gene transcription. This relaxation can be reversed by HDAC activity. Acetylation and deacetylation are typically catalyzed by two groups of enzymes: histone acetyltransferases (HATs) and HDACs. HATs are enzymes that acetylate lysine amino acids of histone proteins by transferring an acetyl group from acetyl coenzyme A to form e-N-acetyllysine. Five families of HATs have been recognized: Gcn5related N-acetyltransferases (GNAT), MOZ-Ybf2/ Sas3-Sas2-Tip60 (MYST), p300/CBP, nuclear hormone receptor coactivators, and TAF1 (formerly TAFII230 in human and TAFII250 in Drosophila) [14] . HDACs are a group of deacetylating enzymes that remove acetyl groups from e-amino groups of lysine residues of histones and nonhistones, causing the condensation of chromatin structure and thereby generally repressing gene expression [15, 16] . There are four classes of HDACs: class I HDACs (HDAC1, 2, 3, and 8); class II HDACs (HDAC 4, 5, 6, 7, 9, and 10); class III (SIRT1-7); and class IV (HDAC 11).
Studies have demonstrated that activation of HATs and HDACs is critically involved in renal regeneration after AKI. As mentioned above, proliferation of renal epithelial cells is a critical step during kidney regenerative process after AKI. Invitro and in-vivo studies have shown that histone acetyltransferase binding to origin recognition complex-1 (HBO1) and gene for apoptosis and differentiation-1 (JADE1) isoform JADE1S is required for epithelial cell proliferation [17] . JADE1 deficiency leads to degradation of HBO1 and prevents cellcycle progression in cultured renal epithelial cells. The JADE1S-HBO1 complex specifically marks the acetylation of histone H4 on lysines 5 and 12 and accumulates during epithelial cell regeneration, indicating a crucial role for JADE1S-HBO1 in kidney regeneration after IR-induced AKI [17] . Epigenetic modulation has also been shown to be involved in the pathogenesis of endotoxin hyper-responsiveness of cytokine production in AKI. In the unilateral
KEY POINTS
Epigenetic modifications including acetylation, methylation, and miRNA expression occur in the kidney after acute injury.
Increased acetylation is associated with damage of renal tubular cells and disruption of renal regenerative processes after AKI.
AKI is associated with changes in DNA methylation, and aberrant DNA promoter hypermethylation can be considered to be a biomarker of AKI. miRNA can target both renal injury and regenerative processes in AKI depending on which miRNA is involved.
renal I/R-induced mouse AKI model, lipopolysaccharide (LPS) triggers histone acetylation epigenetic pathways that interact at the tumor necrosis factor alpha (TNF-a) gene to generate endotoxin hyperresponse in AKI [18] .
Our recent studies indicated that inhibiting class I HDAC activity with a highly selective inhibitor MS-275, or silencing HDAC1, 3, or 8 with small interfering RNA induced global histone H3 hyperacetylation, decreased cell proliferation, and reduced expression of cyclin D1 and proliferating cell nuclear antigen in cultured renal proximal tubular cells, suggesting a role for class I HDACs in mediating renal tubular cell proliferation [19 & ]. Further in-vivo studies showed that blockage of class I HDACs with MS-275 resulted in more severe tubular injury in the mouse model of AKI induced by folic acid or rhabdomyolysis, as evidenced by worsening renal dysfunction, increased NGAL expression, and ]. These data illustrated that class I HDACs activity is required for renal repair and renal regeneration after AKI. The renoprotective effect of HDACs in kidney injury is consistent with reports by other groups. Marumo et al. [21 & ] also found that I/R of the mouse kidney induced a transient decrease in histone acetylation in the ischemic period, and subsequently downregulation of HDAC5 during the recovery phase, resulting in histone re-acetylation and induction of bone morphogenetic protein-7 in proximal tubular cells. Bone morphogenetic protein-7 is a key developmental factor in nephron formation during kidney development and is required for the proliferation and repair of the tubular cells after ischemia [22, 23] . Thus, HDAC5 inhibition may serve as a potential therapeutic strategy for accelerating regeneration of the injured kidney. Furthermore, Hsing et al. [24] showed that decreasing HDAC2 and HDAC5 expression levels is in parallel with increasing acetyl histone H3 and associated with the renoprotective effect of dexmedetomidine, and a2-adrenoceptor agonist, in sepsis-induced AKI.
It should be noted that HDAC inhibition with phenylthiobutanoic acids, another class I HDAC inhibitor, has been reported to enhance renal recovery and attenuate renal fibrosis. This was demonstrated in animal models of I/R and aristolochic acid induced AKI when M4PTB is administered at 24 h after ischemic injury or 4 days after injection of aristolochic acid [25] . The effects of M4PTB seem to be in contrast to the observations made using MS-275; however, the antifibrotic effects were also observed when MS-275 was administered in an animal model of renal fibrosis induced by unilateral ureteral obstruction [26] . Thus, inhibition of renal fibrosis may be, at least in part, responsible for the beneficial effect of HDAC inhibitors in promoting renal regeneration and renal functional recovery.
In conclusion, protein acetylation plays an important role in the pathogenesis and regeneration of AKI. Future studies are needed to identify the specific HDAC isoforms and acetylated proteins involved in these processes of AKI.
METHYLATION AND ACUTE KIDNEY INJURY
Methylation contributes to epigenetic inheritance and is carried out through either DNA methylation or protein methylation. DNA methylation refers to the addition of methyl groups (CH3) from S-adenosyl methionine (SAM-CH3) to the cytosine or adenine DNA nucleotides. It is catalyzed by a family of DNA methyltransferases. DNA methylation plays an important role in epigenetic gene modulation during development and diseases, including AKI. It was first reported by Pratt et al. [27 & ] that DNA methylation status was changed in the rat kidney after I/R-induced AKI. Subsequently, aberrant DNA promoter hypermethylation was considered to be a biomarker of AKI. For example, kidney transplant recipients were significantly more likely to have aberrant hypermethylation of the calcitonin (CALCA) gene promoter in urine than healthy controls. Furthermore, there was a trend toward increased aberrant hypermethylation of urine CALCA in patients with biopsy-proven acute tubular necrosis versus acute rejection and slow or prompt graft function [28] . Plasma levels of unmethylated DNA corresponding to the Slc22a12 promoter region, a urate transporter specifically expressed in proximal tubular cells, were undetectable at baseline and were significantly elevated after acute kidney cortex necrosis [29] . Methylation of promoter kallikrein (KLK1) CpG in the kidney was higher in blood than urine DNA, whereas KLK1 methylation in blood DNA was higher in established AKI than healthy controls, although KLK1 methylation in urine tended to be elevated in AKI, directionally consistent with earlier/incipient but not later/established changes in KLK1 excretion in AKI [30] . Huang et al. [31] further showed that the global level of 5-hydroxymethylcytosine (5hmC) was reduced in I/R injured mouse. I/R injury also decreased the 5hmC enrichment at promoter regions of Cxcl10 and Ifngr2 genes, contributing to the increased levels of Cxcl10 and Ifngr2 mRNA in I/R-injured kidney [31] . These studies suggest the change of DNA methylation in acute renal injury. Further studies are needed to examine the relationship between cytosine methylation and AKI.
Differently from acetylation correlated with an 'open' chromatin state and the activation of gene expression, histone methylation changes transcription though creating docking sites for chromatin modifiers and has more diverse outcomes -active, poised, or repressive status of chromatin and transcriptional marks. The known methylated sites consist of the lysine residues K4, K9, K23, K27, K36, K56, and K79 in H3, K20 in H4, K26 in H1, and four arginine (R) residues (R2, R8, R17, and R26) in H3, R3 in H4, and R11 and R29 in H2A. Generally, methylation at H3K4, H3K36, and H3K79 is associated with the activation of gene transcription, whereas methylation at H3K9, H3K27, and H4K20 is related to the repression of gene transcription [32] . Methylation of histone lysine or arginine residues is modulated by methyltransferases and demethylases. Histone methyltransferases include two major types, lysine-specific (KMT) and arginine-specific (RMT). Lysine-specific demethylases (LSD or KDM) include six LSD families, from KDM1 to KDM6.
There are few studies exploring the role of histone methylation in AKI. It was reported that histone 3 lysine 4 trimethylation (H3K4m3) levels at the first and last exons of the TNF-a gene were higher in postischemic kidneys, compared with contralateral kidneys [33] . Increased levels of H3K4m3 at exon 1 of the HMG-CoA reductase (HMGCR) gene contributes to an upregulation of HMGCR activity in patients with AKI [34] . Increased H3K4m3 at exons of monocyte chemoattractant-1 (MCP-1) and TNF-a gene corresponds to increases in the recruitment of RNA polymerase II to the TNF-a and MCP-1 genes in three highly divergent models of acute renal injury (LPS-preconditioning, maleate nephrotoxicity, and unilateral ureteral obstruction) [35] . Currently, it remains unclear whether modulation of histone methylation would alter the pathogenesis and regenerative responses after AKI.
Nevertheless, emerging evidence indicates that histone methylation is involved in the regulation of cell differentiation and proliferation. For example, LSD1, which demethylates histone H3 on Lys4 or Lys9 (H3K4/K9), is necessary for decommissioning enhancers during the differentiation of mouse embryonic stem cells (ESC) so as to allow the transition of ESC to new cell states [36] . The interaction of H3K27me3, H3K36me3, H3K4me1/2/3, or H3K9me3, with polycomb group proteins is essential to preserve stemness and regulate differentiation of epidermal stem cells [37] . Moreover, accumulation of histone methylation by administration of trans-2-phenylcyclopropylamine (2-PCPA), an LSD1 inhibitor, was shown to suppress proliferation of neuromast cells and to enhance cellular apoptosis within neuromasts during zebrafish development [38] , suggesting that LSD1 contributes to growth and survival of neuromasts. As survival, proliferation, and differentiation of epithelial tubular cells are critical steps of renal regeneration during AKI, histone methylation might also be involved in these processes. Further studies are needed to address the role of histone methylation in AKI by utilizing pharmacological and genetic approaches.
MIRNA AND ACUTE KIDNEY INJURY
miRNA are a family of endogenous, short noncoding RNA molecules that regulate gene expression at the posttranscriptional level, thus implicating themselves in diverse cellular processes including development, cell differentiation and proliferation, cell cycle, and apoptosis and metabolism [39] [40] [41] . It has been demonstrated that miRNAs are involved in the pathogenesis of kidney diseases, including AKI. The significance of miRNA in AKI was first revealed in a mouse model in which proximal tube-specific Dicer, a critical enzyme for miRNA production, was knocked out, in which over 80% miRNAs were depleted [42 && ]. Downregulation of miRNA in the renal cortex was shown a remarkable renal protective effect as evidenced by better renal function, less tissue damage, lower tubular apoptosis, and improved survival compared to their wild-type littermates during acute renal I/R injury [42 && ]. Consistent with these observations, further studies also showed that miRNA containing microvesicles protected the kidney against ischemic AKI [43] .
So far, a number of specific miRNAs including miRNA-24, miRNA-494, miRNA-21, and miRNA-127 have been demonstrated to play roles in AKI. Expression of miRNA-24 was upregulated in the mouse kidney after I/R injury and in patients after kidney transplantation [44] . Overexpression of miRNA-24 induced apoptotic responses and altered functional parameters, while silencing of miRNA-24 ameliorated apoptosis and rescued functional parameters during hypoxic conditions in renal endothelial and tubular epithelial cells [44] . An in-vivo study also showed that the silencing of miRNA-24 in mice before I/R injury resulted in a significant improvement in survival and kidney function, a reduction of apoptosis, improved histologic tubular epithelial injury, and less infiltration of inflammatory cells [44] . These results indicate that miRNA-24 promotes renal ischemic injury by stimulating apoptosis in endothelial and tubular epithelial cells, suggesting that inhibition of miRNA-24 might be a promising therapeutic option in the treatment of patients with ischemic AKI.
miRNA-494 was also upregulated in the kidney tissues after I/R injury, which significantly attenuated the level of activating transcription factor 3 and promoted inflammatory mediators, including IL-6, monocyte chemotactic protein-1 (MCP-1), and P-selectin, and nuclear factor kappaB (NF-kB)dependent proinflammatory response, exacerbating apoptosis and further decreasing renal function [45] . Urinary levels of miRNA-494 increased significantly before the rise in serum in this I/R model and in patients with AKI than normal controls [45] . Therefore, upregulation of miRNA-494 contributes to inflammatory or adhesion molecule-induced kidney injury after I/R injury by inhibiting expression of activating transcription factor 3. Furthermore, miRNA-494 may be a specific and noninvasive biomarker for AKI.
In-vitro, knockdown of miRNA-21 in tubular epithelial cells resulted in increased cell death, whereas its overexpression prevented cell death [46] . In-vivo studies also indicate that preconditioning-induced upregulation of miRNA-21 protects against renal I/R injury by the targeted genes such as the proapoptotic gene programmed cell death 4 and interactions between miRNA-21 and hypoxiainducible factor (HIF) [47] . This suggests a protecting role of miRNA-21 in AKI. Another species of miRNA, miRNA-127, which is a critical regulator of cell-cell and cell-matrix adhesion, protects proximal tubule cells against renal I/R injury through HIF-1 and by targeting Kinesin Family Member 3B, with important implications in cell endocytosis [48] . A very recent study has further shown that under hypoxic and ischemic conditions, miRNA-687 can be induced via HIF-1 and upon induction, miRNA-687 represses phosphatase and tensin homolog (PTEN) and then facilitate cell-cycle activation for tubular cell proliferation and kidney repair [49 && ]. These studies indicate that miRNA can target both renal injury and regenerative processes in AKI and suggest that regulation of miRNA expression holds a therapeutic potential for treatment of ischemic renal injury.
OTHER HISTONE MODIFICATIONS AND ACUTE KIDNEY INJURY
In addition to histone modifications, histone phosphorylation and sumoylation have also been reported to be involved in the process of AKI. Histone phosphorylation can occur on serine, threonine, and tyrosine residues and is involved in DNA damage repair, transcription regulation, and chromatin compaction [50] . Available evidence indicates that histone phosphorylation plays a role in a cross-talk with other histone modifications, including acetylation [51] and methylation [52] . Studies demonstrate that phosphorylation of serines 10 and 28 of H3 and serine 32 of H2B is associated with regulation of epidermal growth factor (EGF)responsive gene transcription [50] . As EGF and EGF receptor have been shown to be critically implicated in renal regeneration after AKI [53, 54] , it is speculated that this modification may also affect renal repair and renal functional recovery.
Sumoylation is a form of posttranslational modification by which small ubiquitin-like modifiers (SUMO) are covalently attached to target proteins to regulate their properties. A study by Dong et al. indicated that a dynamic change of renal protein sumoylation occurred in ischemic and cisplatin nephrotoxic AKI in mice and that inhibition of sumoylation with ginkgolic acid, a pharmacological inhibitor of sumoylation, enhanced apoptosis during cisplatin incubation. This suggests a cytoprotective role for sumoylation in kidney tubular cells after injury [55] .
Although other histone modifications, such as ubiquitinylation, ADP ribosylation, deamination, carbonylation, and glycosylation have also been reported in diverse diseases [56] [57] [58] [59] [60] , there is no available information on their modifications and implications in AKI.
CONCLUSION AND PERSPECTIVE
Although progress has been made in understanding the molecular basis of AKI, the therapeutic treatment for AKI is still limited to supportive care and renal replacement therapy in the event of no return of function. Recent advances in understanding epigenetic regulation allow us to explore epigenetic therapies for this disease. Increasing evidence indicates that the pathogenesis of AKI, in particular the renal regenerative processes, is subjected to at least three types of epigenetic regulations (acetylation, methylation, and miRNA; Table 1 ). Epigenetic modifiers are also aberrantly expressed during AKI, which might be a promising biomarker for AKI. However, the underlying mechanism by which epigenetic regulation contributes to AKI initiation and progression remains incompletely understood. Thus, further dissection of epigenetic regulations on these processes would provide the cellular and molecular basis for epigenetic therapy in AKI. Although those aforementioned epigenetic mechanisms are linked to the pathogenesis of AKI, the cross-talk among various epigenetic regulations in AKI remains unclear. Clearly, a cross-talk between miRNA and methylation and acetylation exists in cancers. It has been shown that expression of some miRNAs, such as let-7a, miRNA-9, miRNA-34a, miRNA-124, miRNA-137, miRNA-148, and miRNA-203, can be modulated by DNA methylation and histone modifications [61] [62] [63] [64] [65] . Conversely, DNA methylation and histone acetylation are also controlled by a subset of miRNAs [66] . N-terminal acetylation of H4 was discovered as a novel regulator of arginine methylation and this cross-talk-regulated ribosomal DNA silencing [67] . The integrative network between these three epigenetic pathways appears to establish an acetylation-methylation-miRNA regulatory loop intertwined with the transcriptional and posttranscriptional pathways, which opens new doors for potential cross-talk events and chromatin signaling networks [66] . Future studies are needed to identify the specific proteins targeted by epigenetic regulation and the molecular basis by which the epigenetic modifiers are regulated during AKI. A better understanding of the role of epigenetics in AKI will lead to the development of new drugs and specific treatment strategies.
].
Methylation
Aberrant DNA promoter hypermethylation was considered to be a biomarker of AKI Aberrant hypermethylation of the calcitonin gene promoter is higher in urine than healthy controls [28] KLK1 methylation in blood DNA is higher in established AKI than healthy controls [30] Increases in the recruitment of RNA polymerase II to the TNF-a and MCP-1 genes during AKI [35] MicroRNA Aggravate or protect against renal ischemic injury miRNA-24 promotes renal ischemic injury by stimulating apoptosis in endothelial and tubular epithelial cells and facilitating infiltration of inflammatory cells in I/R injury kidney [44] miRNA-494 inhibits expression of ATF3 and promotes inflammatory mediators, including interleukin-6 (IL-6), MCP-1, and P-selectin, exacerbating apoptosis and decreasing renal function in the kidney after I/R injury [45] Upregulation of miRNA-21 protects against renal I/R injury by the targeted genes such as the proapoptotic gene programmed cell death 4 and interactions between miRNA-21 and hypoxia-inducible factor (HIF) [47] miRNA-687 represses PTEN and then facilitates cell cycle activation for tubular cell proliferation and kidney repair under hypoxic and ischemic conditions [49 && ] miRNA-127 protects proximal tubule cells against renal I/R injury through HIF-1 and by targeting Kinesin Family Member 3B (KIF3B) [48] AKI, acute kidney injury; EGFR, epidermal growth factor; KLK1, kallikrein; MCP-1, monocyte chemotactic protein-1; miRNA, microRNA; PTEN, phosphatase and tensin homolog; STAT3, signal transducer and activator of transcription 3. 
